Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Carcinoma, Non-Small-Cell Lung | 14 | 2019 | 896 | 2.13 | Why? |
| Lung Neoplasms | 21 | 2019 | 3228 | 2.11 | Why? |
| Venous Thromboembolism | 10 | 2021 | 4273 | 1.99 | Why? |
| Small Cell Lung Carcinoma | 4 | 2018 | 133 | 1.54 | Why? |
| ErbB Receptors | 4 | 2018 | 320 | 1.26 | Why? |
| Anticoagulants | 5 | 2021 | 9563 | 0.75 | Why? |
| Chromosomes, Human, Pair 7 | 1 | 2017 | 5 | 0.72 | Why? |
| Aneuploidy | 1 | 2017 | 27 | 0.70 | Why? |
| Biomarkers, Tumor | 8 | 2019 | 1314 | 0.69 | Why? |
| Neoplastic Cells, Circulating | 1 | 2018 | 68 | 0.69 | Why? |
| Disease-Free Survival | 5 | 2018 | 1654 | 0.69 | Why? |
| Programmed Cell Death 1 Receptor | 3 | 2019 | 724 | 0.67 | Why? |
| Platelet Transfusion | 1 | 2018 | 209 | 0.66 | Why? |
| Everolimus | 1 | 2018 | 215 | 0.61 | Why? |
| Sarcoidosis | 1 | 2018 | 271 | 0.55 | Why? |
| Catheter Ablation | 1 | 2017 | 438 | 0.48 | Why? |
| B7-H1 Antigen | 5 | 2019 | 541 | 0.44 | Why? |
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 130 | 0.43 | Why? |
| Pneumonectomy | 1 | 2014 | 278 | 0.43 | Why? |
| Cancer Survivors | 1 | 2017 | 588 | 0.40 | Why? |
| Atherosclerosis | 1 | 2018 | 768 | 0.40 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 1510 | 0.39 | Why? |
| Hemorrhage | 2 | 2018 | 3013 | 0.38 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2017 | 1731 | 0.36 | Why? |
| B7 Antigens | 2 | 2017 | 18 | 0.36 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.34 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2019 | 1573 | 0.33 | Why? |
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 5993 | 0.33 | Why? |
| Colorectal Neoplasms | 2 | 2018 | 1884 | 0.32 | Why? |
| Sleep Wake Disorders | 1 | 2018 | 1463 | 0.31 | Why? |
| Thrombophilia | 1 | 2018 | 1935 | 0.30 | Why? |
| Chemoradiotherapy | 2 | 2019 | 362 | 0.30 | Why? |
| Neoplasms | 4 | 2018 | 17251 | 0.30 | Why? |
| Greece | 4 | 2021 | 2091 | 0.30 | Why? |
| Venous Thrombosis | 1 | 2021 | 2739 | 0.30 | Why? |
| Immunotherapy | 2 | 2018 | 2421 | 0.29 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.29 | Why? |
| Thrombocytopenia | 1 | 2018 | 2093 | 0.29 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.28 | Why? |
| Mutation | 5 | 2018 | 12376 | 0.28 | Why? |
| Hypertension, Pulmonary | 1 | 2014 | 970 | 0.28 | Why? |
| Diet | 1 | 2017 | 2052 | 0.28 | Why? |
| Tissue Array Analysis | 4 | 2017 | 75 | 0.27 | Why? |
| Troponin | 2 | 2020 | 1058 | 0.26 | Why? |
| Antibodies, Monoclonal | 3 | 2018 | 8041 | 0.24 | Why? |
| Neoplasm Staging | 6 | 2019 | 1999 | 0.23 | Why? |
| Erlotinib Hydrochloride | 2 | 2018 | 48 | 0.23 | Why? |
| Pulmonary Embolism | 1 | 2021 | 4775 | 0.22 | Why? |
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 1014 | 0.22 | Why? |
| Carcinoma, Squamous Cell | 3 | 2018 | 902 | 0.21 | Why? |
| GRB2 Adaptor Protein | 1 | 2018 | 5 | 0.20 | Why? |
| Antigens, CD | 3 | 2021 | 984 | 0.20 | Why? |
| Genes, erbB | 1 | 2018 | 2 | 0.20 | Why? |
| Taxoids | 2 | 2017 | 45 | 0.20 | Why? |
| Ipilimumab | 1 | 2019 | 102 | 0.19 | Why? |
| Tubulin Modulators | 1 | 2020 | 126 | 0.19 | Why? |
| Phosphatidate Phosphatase | 1 | 2018 | 5 | 0.19 | Why? |
| Humans | 44 | 2021 | 930598 | 0.19 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.19 | Why? |
| Organoplatinum Compounds | 1 | 2018 | 76 | 0.18 | Why? |
| Phosphoric Diester Hydrolases | 1 | 2018 | 52 | 0.18 | Why? |
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 98 | 0.18 | Why? |
| Capecitabine | 1 | 2018 | 51 | 0.18 | Why? |
| Aged | 25 | 2021 | 215776 | 0.18 | Why? |
| Centromere | 1 | 2017 | 12 | 0.18 | Why? |
| Chromosome Duplication | 1 | 2017 | 6 | 0.18 | Why? |
| V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2017 | 4 | 0.18 | Why? |
| Registries | 1 | 2018 | 12327 | 0.18 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.17 | Why? |
| Survival Rate | 5 | 2019 | 9206 | 0.17 | Why? |
| Cell Count | 1 | 2018 | 228 | 0.17 | Why? |
| Gene Amplification | 1 | 2017 | 85 | 0.17 | Why? |
| Lysophospholipids | 1 | 2018 | 74 | 0.17 | Why? |
| Microwaves | 1 | 2017 | 88 | 0.16 | Why? |
| Prognosis | 9 | 2021 | 32490 | 0.16 | Why? |
| In Situ Hybridization, Fluorescence | 1 | 2017 | 207 | 0.16 | Why? |
| Aged, 80 and over | 12 | 2021 | 88759 | 0.15 | Why? |
| Middle Aged | 22 | 2021 | 270681 | 0.15 | Why? |
| Thrombosis | 1 | 2018 | 7504 | 0.15 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.15 | Why? |
| In Situ Hybridization | 1 | 2017 | 390 | 0.15 | Why? |
| Topotecan | 1 | 2015 | 62 | 0.15 | Why? |
| Postoperative Complications | 1 | 2014 | 5861 | 0.14 | Why? |
| Chemotherapy, Adjuvant | 1 | 2018 | 606 | 0.14 | Why? |
| Male | 26 | 2021 | 367725 | 0.14 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.14 | Why? |
| Cardiotoxicity | 1 | 2018 | 365 | 0.14 | Why? |
| Immunohistochemistry | 3 | 2017 | 2275 | 0.14 | Why? |
| Kaplan-Meier Estimate | 3 | 2020 | 4260 | 0.14 | Why? |
| Costs and Cost Analysis | 1 | 2019 | 694 | 0.14 | Why? |
| Treatment Outcome | 11 | 2021 | 51732 | 0.14 | Why? |
| Female | 26 | 2021 | 380317 | 0.14 | Why? |
| Vitamin K | 1 | 2016 | 263 | 0.14 | Why? |
| Fluorescent Antibody Technique | 1 | 2017 | 835 | 0.13 | Why? |
| Survival Analysis | 5 | 2019 | 7592 | 0.13 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.13 | Why? |
| Colchicine | 1 | 2020 | 730 | 0.13 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2021 | 1165 | 0.12 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.12 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.12 | Why? |
| Geography | 1 | 2018 | 1801 | 0.11 | Why? |
| Dose-Response Relationship, Drug | 1 | 2021 | 3776 | 0.11 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2020 | 994 | 0.11 | Why? |
| Mass Spectrometry | 1 | 2017 | 1165 | 0.11 | Why? |
| Hospitalization | 2 | 2021 | 54280 | 0.10 | Why? |
| Brain Neoplasms | 1 | 2017 | 669 | 0.10 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.10 | Why? |
| Perception | 1 | 2021 | 2827 | 0.10 | Why? |
| Telemedicine | 1 | 2021 | 25032 | 0.10 | Why? |
| Adult | 12 | 2021 | 244371 | 0.10 | Why? |
| Administration, Oral | 1 | 2016 | 2340 | 0.10 | Why? |
| Proteins | 1 | 2017 | 921 | 0.09 | Why? |
| Protein Kinases | 1 | 2009 | 93 | 0.09 | Why? |
| Single-Cell Analysis | 1 | 2019 | 2450 | 0.09 | Why? |
| Antigens, Differentiation, Myelomonocytic | 2 | 2021 | 198 | 0.09 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.09 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.09 | Why? |
| Retreatment | 2 | 2019 | 186 | 0.08 | Why? |
| Membrane Proteins | 1 | 2017 | 1733 | 0.08 | Why? |
| Cohort Studies | 5 | 2018 | 36005 | 0.08 | Why? |
| Quinazolines | 2 | 2017 | 126 | 0.08 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.08 | Why? |
| Fibrinolytic Agents | 1 | 2017 | 1702 | 0.08 | Why? |
| Cell Line, Tumor | 4 | 2017 | 3608 | 0.07 | Why? |
| Risk Assessment | 2 | 2021 | 25439 | 0.07 | Why? |
| Inpatients | 1 | 2021 | 5161 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.06 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Antineoplastic Agents | 2 | 2017 | 3550 | 0.06 | Why? |
| Adenocarcinoma | 1 | 2009 | 651 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
| ROC Curve | 1 | 2014 | 6024 | 0.06 | Why? |
| Incidence | 2 | 2021 | 25622 | 0.06 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.05 | Why? |
| Carboplatin | 1 | 2019 | 76 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2021 | 7301 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2018 | 6331 | 0.05 | Why? |
| Receptors, Lysophosphatidic Acid | 1 | 2018 | 4 | 0.05 | Why? |
| Urethane | 1 | 2018 | 4 | 0.05 | Why? |
| Quality of Life | 2 | 2017 | 9820 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Paclitaxel | 1 | 2019 | 124 | 0.05 | Why? |
| Injections, Subcutaneous | 1 | 2021 | 647 | 0.05 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.05 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.05 | Why? |
| Neoplasms, Experimental | 1 | 2018 | 67 | 0.05 | Why? |
| Receptors, Urokinase Plasminogen Activator | 1 | 2021 | 252 | 0.04 | Why? |
| HT29 Cells | 1 | 2017 | 108 | 0.04 | Why? |
| Albumins | 1 | 2019 | 324 | 0.04 | Why? |
| Tissue Fixation | 1 | 2017 | 85 | 0.04 | Why? |
| Paraffin Embedding | 1 | 2017 | 105 | 0.04 | Why? |
| MCF-7 Cells | 1 | 2017 | 199 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Receptors, Cell Surface | 1 | 2021 | 586 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Response Evaluation Criteria in Solid Tumors | 1 | 2015 | 37 | 0.04 | Why? |
| Platinum Compounds | 1 | 2015 | 20 | 0.04 | Why? |
| Evaluation Studies as Topic | 1 | 2017 | 391 | 0.04 | Why? |
| Tumor Suppressor Protein p53 | 1 | 2018 | 310 | 0.04 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.03 | Why? |
| Interleukin-10 | 1 | 2021 | 1409 | 0.03 | Why? |
| Standard of Care | 1 | 2021 | 1297 | 0.03 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.03 | Why? |
| Sensitivity and Specificity | 1 | 2014 | 22971 | 0.03 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.03 | Why? |
| Hematologic Tests | 1 | 2017 | 521 | 0.03 | Why? |
| Connecticut | 1 | 2013 | 547 | 0.03 | Why? |
| Drug Resistance, Neoplasm | 1 | 2015 | 447 | 0.03 | Why? |
| Datasets as Topic | 1 | 2018 | 1404 | 0.03 | Why? |
| A549 Cells | 1 | 2017 | 2066 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2013 | 961 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.03 | Why? |
| Disease Progression | 2 | 2020 | 13580 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2019 | 2742 | 0.02 | Why? |
| Lung | 2 | 2018 | 31049 | 0.02 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.02 | Why? |
| Protein Kinase Inhibitors | 1 | 2018 | 1585 | 0.02 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.02 | Why? |
| TOR Serine-Threonine Kinases | 1 | 2009 | 385 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Cause of Death | 1 | 2020 | 4823 | 0.02 | Why? |
| Health Resources | 1 | 2019 | 2592 | 0.02 | Why? |
| Proteomics | 1 | 2017 | 2481 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2017 | 5837 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2019 | 5002 | 0.01 | Why? |
| Brain | 1 | 2017 | 5133 | 0.01 | Why? |
| RNA, Messenger | 1 | 2013 | 5131 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2009 | 5440 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 9335 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |